Effect of Dahuang zhechong formula on liver fibrosis in patients with chronic hepatitis B: A meta-analysis

Wei, Feifei; Lang, Yakun; Gong, Dandan; Fan, Yu

doi:10.1016/j.ctim.2014.12.011

Cited by 21 publications

(17 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DaHuangZheChong pill (DHZCP) was a classic recipe in traditional Chinese medicine(TCM), and was o cially approved and recommended for treat liver brosis [11]. Many clinical and experimental studies had con rmed the effect on hepatic brosis [12,13], and de nited that the anti-brotic mechanism was about inhibiting the activation of HSCs [14]. However, it was not enough to elucidate the mechanism for treating hepatic brosis.…”

Section: Introductionmentioning

confidence: 99%

WITHDRAWN: The extract of a Traditional Chinese Medicine alleviates Hepatic Fibrosis of Rats by inhibiting NF-κB activation and upregulating BAMBI in Hepatic Stellate Cells

Li¹,

Tang²,

Lv³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background DaHuangZheChong pill (DHZCP) is a formula of traditional Chinese medicine, which has been written into the guideline for the prevention and treatment of hepatic fibrosis in China. The study was aim to investigate the anti-fibrotic effects and the potential mechanisms of DHZCP revolving around the TGF-β pseudo receptor, bone morphogenic protein and activin membrane-bound inhibitor (BAMBI) in hepatic stellate cells (HSCs). Materials and Methods Wistar rats were given with CCL4 for four weeks to establish hepatic fibrosis model. Then the rats were given normal saline or DHZCP decoction six weeks. the pathology of liver tissue was analyzed, the expression of Toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88), BAMBI, and NF-κB were detected. In vitro, the associated signal molecules about LPS-activated NF-κB were also analyzed by immunohistochemistry, western blot, or electrophoretic mobility shift assay (EMSA) in cultured HSC-T6 cells . Results The DHZCP showed significant effects on improving fibrosis stage of liver tissue and inhibiting primary HSCs activation. The protein expression of TLR4/MyD88 was lower (P was both < 0.05), BAMBI was higher in DHZCP group than model control (MC) group (P < 0.05) in primary HSCs. In HSC-T6 cells, the activity of NF-κB was lower (P < 0.001), and BAMBI was higher (P < 0.05) in DHZCP added LPS group than in LPS group. Conclusion These results suggested that DHZCP alleviates hepatic fibrosis that was maybe associated with inhibiting activation of NF-κB induced by LPS, and upregulating BAMBI expression in HSCs.

show abstract

Section: Introductionmentioning

confidence: 99%

WITHDRAWN: The extract of a Traditional Chinese Medicine alleviates Hepatic Fibrosis of Rats by inhibiting NF-κB activation and upregulating BAMBI in Hepatic Stellate Cells

Li¹,

Tang²,

Lv³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Wei et al, conducted a meta-analysis which included 17 trails including 1212 patients and concluded that DHZCP could reduce the serum biomarker of hepatic fibrosis in CHB patients [11]. By decreasing the secretion of TNF-α and IL-13 and regulating the phosphorylation of p38 and the ERK pathway, DHZCP can protect against liver fibrosis and reverse the expression of aspartate aminotransferase, alanine aminotransferase, hyaluronic acid, collagen, and laminin [12].…”

Section: Introductionmentioning

confidence: 99%

Dynamic Changes in MMP1 and TIMP1 in the Antifibrotic Process of Dahuang Zhechong Pill in Rats with Liver Fibrosis

et al. 2019

View full text Add to dashboard Cite

On the basis of carbon tetrachloride (CCl4)induced liver fibrosis in rats, this study aims to investigate the dynamic changes in matrix metalloproteinase 1 (MMP1) and the tissue inhibitor of metalloproteinase 1 (TIMP1) in the antifibrotic process of Dahuang Zhechong Pill (DHZCP). A total of 50 male Sprague Dawley rats, aged 8 weeks, were randomly divided into 3 groups: the control group, the model group (the group treated with CCl4), and the treatment group (the group treated with CCl4 and DHZCP). Rats were sacrificed at Weeks 4 and 8. Liver tissues were separated for RNA sequencing and bioinformatics analysis. Real-time PCR, Western blot analysis, and histological staining were conducted to confirm the gene expression and pathological change in liver tissues. Compared with control group, rats in model group showed poor mental state and slow weight gain. The liver tissues of the rats in the model group exhibited a damaged hepatic lobule structure, fibrous connective tissue hyperplasia, and inflammatory cell infiltration among the hyperplastic tissues. DHZCP could significantly improve the appearance of rats and alleviate CCl4-induced fibrosis. Compared to model group, 798 differentially expressed mRNAs were found in the treatment group, of which 120 were up-regulated and 678 were down-regulated. Differentially expressed mRNAs between the CCl4-induced group and the DHZCP-treated group were mainly focused on the following KEGG pathways: focal adhesion, phagosome, tight junction, and ECM–receptor interactions. Relative to those in the control group, MMP1 was downregulated, whereas, TIMP1 and Col1A1 were upregulated in the CCl4-induced group at Weeks 4 and 8. DHZCP could reverse MMP1, TIMP1, and Col1A1 expression.DHZCP protects against liver injury and exerts an antifibrotic effect on liver fibrosis induced by CCl4 in rats. Its mechanism may be related to the upregulation of MMP1, downregulation of TIMP1, and promotion of collagen degradation.

show abstract

“…Evidence has shown that promoting blood circulation and removing stasis play important roles in the treatment of inflammation (Ma et al, 2007). DHZCP contains herbs (hirudo, tabanus, peach kernel, and rhubarb) that play critical roles in promoting blood circulation and removing blood stasis (Wei et al, 2015), and the antiinflammatory effects of its active components have been demonstrated. Hirudin, a polypeptide originally obtained from hirudo, reduces leukocyte accumulation and shifts microglia toward the M2 phenotype, which contributes to a reduction in neuroinflammation and an improvement in the outcome of ICH (Li X. et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

DHZCP Modulates Microglial M1/M2 Polarization via the p38 and TLR4/NF-κB Signaling Pathways in LPS-Stimulated Microglial Cells

et al. 2020

View full text Add to dashboard Cite

Intracerebral hemorrhage (ICH) is a disease with a significantly high rate of morbidity, mortality and disability. Inhibition of inflammation is considered a potential strategy for improving the clinical symptoms induced by ICH. The hallmark of neuroinflammation is microglial activation. Microglia can polarize into either the classically activated M1 (proinflammatory) phenotype, exacerbating neuronal damage, or the alternatively activated M2 (antiinflammatory) phenotype, exerting neuroprotection and promoting neuronal recovery. Promoting microglial polarization to the M2 phenotype may be a viable strategy for treating neuroinflammation. Several studies have indicated that promoting blood circulation and removing blood stasis exhibits therapeutic effects on intracerebral hemorrhage. Dahuang Zhechong Pill (DHZCP), a classical recipe that promotes blood circulation and removes blood stasis, has been reported to improve the clinical outcome of ICH. DHZCP has been shown to exert antiinflammatory effects. However, the detailed antiinflammatory mechanism of DHZCP in ICH has rarely been investigated. In this study, DHZCP inhibited lipopolysaccharide (LPS)-induced M1 microglial activation. DHZCP exerted antiinflammatory effects, by inhibiting LPS-induced M1 proinflammatory cytokine (TNF-a and IL-6), and iNOS production and increasing M2 antiinflammatory cytokine (IL-10) production. DHZCP also switched microglial polarization from M1 to M2, as indicated by significantly increased expression of M2 polarization markers (CD209, and CD206) and markedly decreased expression of an M1 polarization marker (CD54). In addition, DHZCP inhibited p38 and TLR4/NF-kB signaling activation, as demonstrated by inhibition of LPS-induced increases in p-p38, TLR4 and nuclear factor kappa B p-65 (NF-kB p-65) protein expression. Taken together, DHZCP modulates microglial M1/M2 polarization via the p38 and TLR4/NF-kB signaling pathways to confer antiinflammatory effects.

show abstract

Effect of Dahuang zhechong formula on liver fibrosis in patients with chronic hepatitis B: A meta-analysis

Cited by 21 publications

References 14 publications

WITHDRAWN: The extract of a Traditional Chinese Medicine alleviates Hepatic Fibrosis of Rats by inhibiting NF-κB activation and upregulating BAMBI in Hepatic Stellate Cells

WITHDRAWN: The extract of a Traditional Chinese Medicine alleviates Hepatic Fibrosis of Rats by inhibiting NF-κB activation and upregulating BAMBI in Hepatic Stellate Cells

Dynamic Changes in MMP1 and TIMP1 in the Antifibrotic Process of Dahuang Zhechong Pill in Rats with Liver Fibrosis

DHZCP Modulates Microglial M1/M2 Polarization via the p38 and TLR4/NF-κB Signaling Pathways in LPS-Stimulated Microglial Cells

Contact Info

Product

Resources

About